RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...

Health officials have confirmed three cases of a new, more dangerous strain of mpox in California, raising concerns about its ...

Rapt Therapeutics said a mid-stage trial of its drug for chronic spontaneous urticaria, a skin condition that causes recurrent, spontaneous hives, showed comparable efficacy and safety to omalizumab, ...

CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...

Health authorities warn of a severe strain of mpox spreading in parts of California in the United States. While cases remain ...

California health officials have reported two cases of a potentially more severe form of mpox that appear to be locally ...

Clade I mpox has been seen in the United States before, but only in people with recent travel abroad. The three cases in ...

Health officials in Los Angeles County said on Friday they are investigating a possible local spread of a more severe strain ...

Investing.com -- RAPT Therapeutics Inc (NASDAQ:RAPT) stock surged 56.3% in premarket trading Monday following the announcement of positive topline data from a Phase 2 trial of its RPT904 treatment for ...

The Los Angeles County Department of Public Health is looking into a possible local spread of a more severe strain of the ...

With U.S. diagnoses of Parkinson's expected to reach 1.2 million by 2030, research is in full swing, and treatments ...

The U.S. has more than 1,500 confirmed measles cases, the most since 1992. And Ohio cases are growing. What to know.